Equities

Turnstone Biologics Corp

TSBX:NMQ

Turnstone Biologics Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.25
  • Today's Change-0.06 / -2.60%
  • Shares traded3.70k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Turnstone Biologics Corp. is a clinical-stage biotechnology company. The Company is focused on developing new medicines to treat and cure patients with solid tumors. It is developing tumor infiltrating lymphocytes (TIL) therapies for the potential treatment of multiple solid tumors. It is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. It is advancing TIDAL-01, its lead Selected TIL product candidate, for the treatment of multiple solid tumor indications. TIDAL-01 utilizes an unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of tumor-reactive TILs from the patient’s tumor. Its next Selected TIL program, TIDAL-02, is being designed to encompass a next generation streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.

  • Revenue in USD (TTM)0.00
  • Net income in USD-74.92m
  • Incorporated2014
  • Employees82.00
  • Location
    Turnstone Biologics Corp9310 Athena Circle, Suite 300LA JOLLA 92037United StatesUSA
  • Phone+1 (347) 897-5988
  • Fax+1 (302) 655-5049
  • Websitehttps://www.turnstonebio.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Fortress Biotech Inc85.11m-62.86m39.50m186.00--1.48--0.464-6.65-6.657.961.190.39762.274.55457,602.20-64.47-52.50-107.85-99.4668.2563.17-162.17-236.941.21-10.181.07--11.5825.7527.42---9.37--
Qilian International Holding Group Ltd46.47m-7.78m40.25m298.00--0.9407--0.8662-1.09-1.096.505.980.80276.4533.30155,944.60-14.032.71-16.843.863.7711.66-17.482.724.43-0.48120.010726.11-28.35-1.60-822.64--12.86--
Ocuphire Pharma Inc19.01m-11.30m40.96m14.00--0.8606--2.15-0.4867-0.48670.83661.840.391--4.521,357,929.00-23.24-58.31-25.89-65.94-----59.44-137.92---7.800.00---52.20---155.83------
Eyenovia Inc8.78k-32.44m42.23m57.00--20.03--4,809.50-0.7448-0.74480.00020.03840.0003--0.008154.04-116.94-80.31-190.14-117.700.00---369,519.70-680.950.6645-16.030.8914------2.68--152.20--
Incannex Healthcare Inc-100.00bn-100.00bn43.49m----3.08----------0.8907-----------54.94---59.47-------1,033.07----0.00--61.923.38-24.35--54.12--
United-Guardian, Inc.11.57m2.75m44.03m25.0016.013.9415.423.810.59870.59872.522.430.9263.176.40462,790.8022.0229.8425.9434.3948.6455.3123.7828.795.99--0.0097.37-14.28-4.140.4616-9.9217.19-19.73
Bright Green Corp0.00-11.46m49.82m5.00--4.48-----0.0631-0.06310.000.05840.00----0.00-56.05---84.87-------------18,125.840.0289------52.54------
Odonate Inc0.00-102.07m50.02m137.00--1,844.41-----13.59-13.590.009.270.00----0.00-66.98-58.36-83.00-65.14------------0.00-------12.99------
Turnstone Biologics Corp0.00-74.92m52.04m82.00--0.6504-----3.53-3.530.003.460.00----0.00-80.25---94.45--------------0.00---73.66---78.05------
Rockwell Medical Inc86.62m-8.42m53.60m237.00--2.53--0.6188-0.3584-0.35843.330.69841.9013.2810.12365,485.20-18.47-46.29-27.53-65.3810.594.66-9.72-36.511.38-3.540.331--14.845.6954.82--76.21--
CEL-SCI Corp0.00-29.95m59.58m43.00--4.16-----0.6304-0.63040.000.26450.00-------87.78-70.19-103.56-78.31-------15,434.151.18-39.260.4319------13.99--223.59--
Gritstone bio Inc15.65m-144.89m62.04m231.00--4.01--3.97-1.57-1.570.170.14230.0901--40.5367,727.27-83.47-48.08-97.70-55.18-----926.13-573.71---554.880.7428---18.0568.96-15.71---4.19--
Immix Biopharma Inc0.00-18.21m64.72m14.00--2.32-----0.9263-0.92630.001.060.00----0.00-77.50---90.46--------------0.00-------87.44------
Data as of Jul 03 2024. Currency figures normalised to Turnstone Biologics Corp's reporting currency: US Dollar USD

Institutional shareholders

30.26%Per cent of shares held by top holders
HolderShares% Held
Point72 Asset Management LPas of 31 Mar 20241.73m7.50%
PFM Health Sciences LPas of 31 Mar 2024920.98k3.98%
BofA Securities, Inc.as of 31 Mar 2024893.55k3.86%
Citadel Advisors LLCas of 31 Mar 2024684.63k2.96%
BlackRock Fund Advisorsas of 31 Mar 2024623.90k2.70%
Sectoral Asset Management, Inc.as of 31 Mar 2024517.65k2.24%
Eventide Asset Management LLCas of 31 Mar 2024458.32k1.98%
Fidelity Management & Research Co. LLCas of 31 Mar 2024440.84k1.91%
ExodusPoint Capital Management LPas of 31 Mar 2024369.78k1.60%
The Vanguard Group, Inc.as of 31 Mar 2024354.21k1.53%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.